1.       Discover biological targets through combinatorial approaches (aptamers, peptides, scFv and Fab antibodies fragments) and advanced highthrouput technologies of DNA sequencing and large-scale mass spectrometry for the control of infectious and chronic diseases, such as: sepsis, Malaria, Leishmaniasis, Tuberculosis, Leprosy, Dengue, Criptococcosis, HIV, HTLV-1/2, Toxoplasmosis, Toxocariasis, Neosporosis, Caseous Lymphadenitis, Mastitis, Prostate Cancer, Breast Cancer, Ovary Cancer, Thyroid Cancer, Rheumatoid Arthritis, Crohn's Diseases (Inflammatory bowel Disease), Intestinal Parasitosis, Allergies, Cardiovascular and Muscular Lesions, with prospects of future applications in diagnostics, therapy and immunoprophylaxis.

2.       Discover bioactive peptides (peptidomimetics that are agonists or antagonists of the production of immune mediators) for future use in new therapeutic strategies of immunomodulation and as vaccine adjuvants.

3.       Develop electrochemical sensors and nanopolymeric electrodes conjugated to nucleic acids and proteins.

4.       Develop bioactivated nanoparticles for biological and medical applications, including their application on spectroscopic methods and imaging technologies.

5.       Develop hybrid nanobiosystems with functionalized nanoparticles and microfluidics technology.

6.       Develop new formulations with multifunctional nanocarriers for the delivery of drugs and vaccines.

7.       Develop multifunctional and/or multimodal nanobiosystems, including imaging, thermotherapy, phototherapy and gene-chemotherapy.

8.       Perform the analysis of genotoxicity, cytotoxicity, mutagenicity, toxicity and immunogenicity of nanomaterials for imaging and drug delivery applications.

9.       Provide technical support and training of human resources associated with the research lines of 26 graduate programs.

10.    Promote the internationalization of the NIST and its associated institutions.